MiR-377 functions as a tumor suppressor in human clear cell renal cell carcinoma by targeting ETS1

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 64-71

  Wang, Ruiyan ^a   Ma, Yanjie ^a   Yu, Dan ^a   Zhao, Jiang ^a   Ma, Peilong ^a  

^a DAQING OILFIELD CO LTD   (China)

Author keywords

ETS1; Human clear cell renal cell carcinoma; MiR 377; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 377; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; ETS1 PROTEIN, HUMAN; MIRN377 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CELL INVASION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LUCIFERASE ASSAY; MTT ASSAY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEIN C-ETS-1; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84927554002     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.01.012     Document Type: Article

References (42)

1. Capitanio U., Cloutier V., Zini L., Isbarn H., Jeldres C., Shariat S.F., et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int 2009, 103:1496-1500.
2. Cancer facts & figures 2014 2014, A.C. Society, American Cancer Society, Atlanta, GA.
3. Vasudev N.S., Selby P.J., Banks R.E. Renal cancer biomarkers: the promise of personalized care. BMC Med 2012, 10:112.
4. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007, 356:115-124.
5. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
6. Makeyev E.V., Maniatis T. Multilevel regulation of gene expression by microRNAs. Science 2008, 319:1789-1790.
7. Bushati N., Cohen S.M. microRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
8. Zamore P.D., Haley B. Ribo-gnome: the big world of small RNAs. Science 2005, 309:1519-1524.
9. Calin G.A., Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394.
10. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011, 12:861-874.
11. Guo Y., Chen Z., Zhang L., Zhou F., Shi S., Feng X., et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008, 68:26-33.
12. Han Y., Chen J., Zhao X., Liang C., Wang Y., Sun L., et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 2011, 6:e18286.
13. Christensen L.L., Holm A., Rantala J., Kallioniemi O., Rasmussen M.H., Ostenfeld M.S., et al. Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. PLoS One 2014, 9:e96767.
14. Chen W.X., Ren L.H., Shi R.H. Implication of miRNAs for inflammatory bowel disease treatment: Systematic review. World J Gastrointest Pathophysiol 2014, 5:63-70.
15. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707.
16. Zhu W., He J., Chen D., Zhang B., Xu L., Ma H., et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One 2014, 9:e87780.
17. Schultz N.A., Dehlendorff C., Jensen B.V., Bjerregaard J.K., Nielsen K.R., Bojesen S.E., et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014, 311:392-404.
18. Ahmed F.E., Ahmed N.C., Vos P.W., Bonnerup C., Atkins J.N., Casey M., et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 2013, 10:93-113.
19. Li X., Zhang Z., Yu M., Li L., Du G., Xiao W., et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci 2013, 14:16226-16239.
20. Formosa A., Markert E.K., Lena A.M., Italiano D., Finazzi-Agro E., Levine A.J., et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 2014, 33:5173-5182.
21. Zhang R., Luo H., Wang S., Chen W., Chen Z., Wang H.W., et al. MicroRNA-377 inhibited proliferation and invasion of human glioblastoma cells by directly targeting specificity protein 1. Neuro Oncol 2014, 16:1510-1522.
22. Wang Q., Wang Y., Minto A.W., Wang J., Shi Q., Li X., et al. MicroRNA-377 is upregulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 2008, 22:4126-4135.
23. Tsirimonaki E., Fedonidis C., Pneumaticos S.G., Tragas A.A., Michalopoulos I., Mangoura D. PKCepsilon signalling activates ERK1/2, and regulates aggrecan, ADAMTS5, and miR377 gene expression in human nucleus pulposus cells. PLoS One 2013, 8:e82045.
24. Beckman J.D., Chen C., Nguyen J., Thayanithy V., Subramanian S., Steer C.J., et al. Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217. J Biol Chem 2011, 286:3194-3202.
25. Sato Y., Kanno S., Oda N., Abe M., Ito M., Shitara K., et al. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci 2000, 902:201-205. [discussion 205-207].
26. Oda N., Abe M., Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol 1999, 178:121-132.
27. Wernert N. The multiple roles of tumour stroma. Virchows Arch 1997, 430:433-443.
28. Wernert N., Raes M.B., Lassalle P., Dehouck M.P., Gosselin B., Vandenbunder B., et al. c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 1992, 140:119-127.
29. Behrens P., Rothe M., Wellmann A., Krischler J., Wernert N. The Ets-1 transcription factor is upregulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001, 194:43-50.
30. Fujimoto J., Aoki I., Toyoki H., Khatun S., Tamaya T. Clinical implications of expression of ETS-1 related to angiogenesis in uterine cervical cancers. Ann Oncol 2002, 13:1598-1604.
31. Khatun S., Fujimoto J., Toyoki H., Tamaya T. Clinical implications of expression of ETS-1 in relation to angiogenesis in ovarian cancers. Cancer Sci 2003, 94:769-773.
32. Mukherjee T., Kumar A., Mathur M., Chattopadhyay T.K., Ralhan R. Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003, 129:430-436.
33. Behrens P., Mathiak M., Mangold E., Kirdorf S., Wellmann A., Fogt F., et al. Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers. Int J Cancer 2003, 107:183-188.
34. Mikami S., Oya M., Mizuno R., Murai M., Mukai M., Okada Y. Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis. Cancer Sci 2006, 97:875-882.
35. Kucejova B., Pena-Llopis S., Yamasaki T., Sivanand S., Tran T.A., Alexander S., et al. Interplay between pVHL and mTORC1 pathways in clear cell renal cell carcinoma. Mol Cancer Res 2011, 9:1255-1265.
36. White N.M., Bao T.T., Grigull J., Youssef Y.M., Girgis A., Diamandis M., et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 2011, 186:1077-1083.
37. Li W., Zang W., Liu P., Wang Y., Du Y., Chen X., et al. MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer. Tumour Biol 2014, 35:10897-10904.
38. Wasylyk B., Hahn S.L., Giovane A. The Ets family of transcription factors. Eur J Biochem 1993, 211:7-18.
39. Seth A., Watson D.K. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005, 41:2462-2478.
40. Buggy Y., Maguire T.M., McGreal G., McDermott E., Hill A.D., O'Higgins N., et al. Over-expression of the Ets-1 transcription factor in human breast cancer. Br J Cancer 2004, 91:1308-1315.
41. Li R., Pei H., Watson D.K. Regulation of Ets function by protein-protein interactions. Oncogene 2000, 19:6514-6523.
42. Hsu T., Trojanowska M., Watson D.K. Ets proteins in biological control and cancer. J Cell Biochem 2004, 91:896-903.